Current Australian pediatric practice in the assessment and treatment of ADHD
- PMID: 23830018
- DOI: 10.1016/j.acap.2013.03.009
Current Australian pediatric practice in the assessment and treatment of ADHD
Abstract
Objective: To study the characteristics of children diagnosed with attention-deficit/hyperactivity disorder (ADHD) in Australia, and the assessment and management practices of their pediatricians.
Methods: A 2-week practice audit was conducted in a large representative sample of Australian general/community pediatricians. Pediatricians completed an audit form for all patients seen. Demographic details, diagnoses, treatments, and referrals made were recorded for each consultation.
Results: A total of 199 pediatricians completed the audit (response rate 66%). There were 1528 consultations with patients with ADHD. Eighty percent of the subjects were male, and mean age at diagnosis was 9.1 years (range 3-19 years). Most patients (60%) had 1 or more comorbidity identified, although the reported rates of anxiety (8%) and oppositional defiant disorder (15%) were lower than expected. Patients with ADHD were more likely than patients with other diagnoses to be seen in private practice settings (76% vs. 65%; P < .001). Children with ADHD were referred to numerous services at diagnosis, most commonly psychology (32%). Stimulant medication or atomoxetine was prescribed for 40% at initial diagnosis and 80% at continuing consultation. Overall, methylphenidate was the most common medication prescribed (63%), with a minority prescribed dexamphetamine, atomoxetine, or clonidine. Eighteen percent were prescribed 2 or more medications. Medication prescription was predicted by age but not by gender or socioeconomic status.
Conclusions: ADHD is the most frequent diagnosis seen by Australian pediatricians, with some patients being seen into early adult life. Comorbidities appear to be inconsistently identified, with some possibly underdiagnosed. Older children are more likely to be prescribed medication.
Keywords: assessment; attention-deficit/hyperactivity disorder (ADHD); audit; pediatrician; stimulant medications.
Crown Copyright © 2013. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Indication and use of drug products used to treat attention-deficit/hyperactivity disorder: a cross-sectional study with inference on the likelihood of treatment in adulthood.J Child Adolesc Psychopharmacol. 2007 Jun;17(3):328-33. doi: 10.1089/cap.2006.0062. J Child Adolesc Psychopharmacol. 2007. PMID: 17630866
-
A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.Pediatrics. 2005 Jan;115(1):e97-104. doi: 10.1542/peds.2004-0953. Pediatrics. 2005. PMID: 15629972
-
Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.Health Technol Assess. 2009 Oct;13(50):iii-iv, ix-xi, 1-120. doi: 10.3310/hta13490. Health Technol Assess. 2009. PMID: 19883527
-
Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.Ann Pharmacother. 2006 Jun;40(6):1134-42. doi: 10.1345/aph.1G582. Epub 2006 May 30. Ann Pharmacother. 2006. PMID: 16735655 Review.
-
Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.Semin Pediatr Neurol. 2010 Dec;17(4):230-6. doi: 10.1016/j.spen.2010.10.005. Semin Pediatr Neurol. 2010. PMID: 21183129 Review.
Cited by
-
Systematic review of meditation-based interventions for children with ADHD.Eur Child Adolesc Psychiatry. 2018 Jan;27(1):9-27. doi: 10.1007/s00787-017-1008-9. Epub 2017 May 25. Eur Child Adolesc Psychiatry. 2018. PMID: 28547119
-
Examining the pharmacological and psychological treatment of child and adolescent ADHD in Australia: Protocol for a retrospective cohort study using linked national registry data.BMJ Open. 2022 Nov 23;12(11):e064920. doi: 10.1136/bmjopen-2022-064920. BMJ Open. 2022. PMID: 36418141 Free PMC article.
-
Waiting Times and Influencing Factors in Children and Adults Undergoing Assessment for Autism, ADHD, and Other Neurodevelopmental Differences.Autism Res. 2025 Apr;18(4):788-801. doi: 10.1002/aur.70011. Epub 2025 Feb 24. Autism Res. 2025. PMID: 39994914 Free PMC article.
-
Investigating Variations in Medicine Approvals for Attention-Deficit/Hyperactivity Disorder: A Cross-Country Document Analysis Comparing Drug Labeling.J Atten Disord. 2024 Sep;28(11):1437-1453. doi: 10.1177/10870547231224088. Epub 2024 Feb 7. J Atten Disord. 2024. PMID: 38327043 Free PMC article.
-
Medicinal Cannabis for Paediatric Developmental, Behavioural and Mental Health Disorders.Int J Environ Res Public Health. 2023 Apr 7;20(8):5430. doi: 10.3390/ijerph20085430. Int J Environ Res Public Health. 2023. PMID: 37107712 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical